DOCSLIB.ORG

WO 2017/122111 Al 20 July 2017 (20.07.2017) P O P C T

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
WO 2017/122111 Al 20 July 2017 (20.07.2017) P O P C T (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date WO 2017/122111 Al 20 July 2017 (20.07.2017) P O P C T (51) International Patent Classification: (81) Designated States (unless otherwise indicated, for every A61K 38/16 (2006.01) A61K 9/00 (2006.01) kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, (21) International Application Number: BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, PCT/IB20 17/050087 DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, (22) International Filing Date: HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KH, KN, January 2017 (09.01 .2017) KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, (25) Filing Language: English NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, (26) Publication Language: English RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, (30) Priority Data: ZA, ZM, ZW. 62/277,506 12 January 2016 (12.01.2016) U S (84) Designated States (unless otherwise indicated, for every (71) Applicant: INTRON BIOTECHNOLOGY, INC. kind of regional protection available): ARIPO (BW, GH, [KR/KR]; #1007, JungAng Induspia V , 138-6 Sangdae- GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, won-Dong, Jungwon-Gu, Seongnam-Si, Gyeonggi-do, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, 462-120 (KR). TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, (72) Inventors: YOON, Seong Jun; #301 Shinhan Apt., LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, Galak2-Dong, Songpa-Ku, Seoul, 138-807 (KR). JUN, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, Soo Youn; #301 Shinhan Apt., Galak2-Dong, Songpa-Ku, GW, KM, ML, MR, NE, SN, TD, TG). Seoul, 138-807 (KR). JUNG, Gi Mo; #301 Shinhan Apt., Galak2-Dong, Songpa-Ku, Seoul, 138-807 (KR). KANG, Published: Sang Hyeon; #507-310 Jugong-5-danzi Apt., 27, Jam- — with international search report (Art. 21(3)) sil-Dong, Songpa-Ku, Seoul, 138-225 (KR). — with sequence listing part of description (Rule 5.2(a)) (74) Agent: MIN, H. Timothy; SIMI, 1 Broadway, 14th Floor, Cambridge, Massachusetts 02142 (US). (54) Title: AN ANTIBACTERIAL COMPOSITION AND A METHOD OF TREATING STAPHYLOCOCCAL INFECTIONS WITH THE ANTIBACTERIAL COMPOSITION Figure 1 Staphylococcus mi e S !¾ i : CTC 5 ί (A) (B) Spot-on-lawn assay Turbidity reduction assay (0.5 l \) TOD50= 13.0 (57) Abstract: A method of treating staphylococcal infections includes administering to a subject an effective amount of an antibac terial composition having a broad bactericidal activity. The antibacterial composition includes a first antibacterial protein consisting of the amino acid sequence as set forth in SEQ. ID. NO: 1 and/or a second antibacterial protein consisting of the amino acid se quence as set forth in SEQ. ID. NO: 2 . An Antibacterial Composition and A Method of Treating Staphylococcal Infections With the Antibacterial Composition The present application claims the benefit of US Provisional Application No. 62/277,506, filed on January 12, 2016, which is incorporated by reference for all purposes as if fully set forth herein. BACKGROUND OF THE INVENTION Field of the Invention [0001] The present invention relates to an antibacterial composition and a method of treating staphylococcal infections with the antibacterial composition. Discussion of the Related Art [0002] Staphylococcus is a genus of Gram-positive bacteria, and can cause a wide variety of diseases in humans and animals through either toxin production or penetration. Staphylococcus'-related illness can range from mild and requiring no treatment to severe and potentially fatal. Over 30 different species of Staphylococcus can infect humans. Manifestations of staphylococcal infections usually depend on the type of infection the organism causes. Common types of infections include the followings: skin infections (e.g., folliculitis, furuncles, impetigo, wound infections, scalded skin syndrome), soft-tissue infections (e.g., pyomyositis, septic bursitis, septic arthritis), toxic shock syndrome, purpura fulminans, endocarditis, osteomyelitis, pneumonia, infections related to prosthetic devices (e.g., prosthetic joints and heart valves; vascular shunts, grafts, catheters), and urinary tract infection. People with suppressed immune systems (those taking immune-suppressing medications or with immune deficiencies) are at increased risk for developing more serious infections. [0003] Staphylococcal infections are usually caused by Staphylococcus aureus. The infections due to other Staphylococcus species have been steadily rising. For example, Staphylococcus saprophytics accounts for up to 10% of uncomplicated urinary tract infections in young women; Staphylococcus schleiferi, Staphylococcus lugdunensis and Staphylococcus haemolyticus are associated with native valve endocarditis. Coagulase-negative Staphylococcus (CoNS) has emerged as a clinically relevant pathogen found in more than 12% of hospitalized inpatients and implicated in up to 30% of healthcare-associated sepsis cases. In addition, many Staphylococcus species are resistant to many antibiotics. [0004] Considering the problems causing by Staphylococcus, it is urgently requested to develop a method for treating staphylococcal infections caused by antibiotic-sensitive and antibiotic-resistant Staphylococcus. Even though antibiotics are still major therapeutic agents for the treatment of such staphylococcal infections, t e antibiotic -based treatment has serious problems such as the reduced treatment outcome. Therefore, to enhance the treatment efficiency for staphylococcal infections, a new efficient alternative (therapeutic agent) is urgently requested. [0005] Recently, the use of endolysins has drawn our attention as a new way of treating bacterial infections. Phage endolysins, also known as phage lysins or lysins, are bacteriophage-encoded, peptidoglycan-degrading enzymes that rapidly degrade bacterial cell walls and release phage progeny. US Patent No. 8,232,370 reported that an antibacterial protein that has antibacterial activity specific to Staphylococcus aureus. [0006] Furthermore, it is widely reported that endolysins have species-specific bactericidal activity. For example, Future Microbiol. 2012 October; 7(10): 1147— 1171 at 1148 reports that "[a]n important advantage of endolysins over classical antibiotics is their high specificity for certain PG [peptidoglycan] types, which generally limits their antimicrobial action to members of a certain bacterial genus, species or even serotype." Applied and Environmental Microbiology, Mar. 2009, p . 1388-1394, at pages 1388-1389, reports that "[bacteriophage lysins] not only exert their lethal effects in the absence of bacteriophage (cause 'lysis from without') but also display specificity for a bacterial host, often for a particular genus, species, or even a subspecies depending on the lysin." Applied and Evironmental Microbiology, Nov. 2002, p. 531 1-5317, at page 5311, reports that "[a]ll 48 tested strains of C. perfringens were sensitive to the murein hydrolase [of the Bacteriophage φ3626 Dual Lysis System], whereas other Clostridia and bacteria belonging to other genera were generally not affected." [0007] Therefore, there is a need to develop antibacterial proteins that have antibacterial activity specific to more than one Staphylococcus species, and thus the infections caused by multiple Staphylococcus species can be treated. SUMMARY OF THE INVENTION [0008] The present invention provides a method of treating staphylococcal infections. The method includes administering to a subject an effective amount of an antibacterial composition having a broad bactericidal activity against at least one of or all following Staphylococcus species: Staphylococcus arlettae, Staphylococcus aureus, Staphylococcus auricularis, Staphylococcus carnosus, Staphylococcus carprae, Staphylococcus chromogenes, Staphylococcus cohnii, Staphylococcus delphini, Staphylococcus epidermidis, Staphylococcus equorum, Staphylococcus gallinarum, Staphylococcus hemolyticus, Staphylococcus hominis, Staphylococcus intermedius, Staphylococcus kloosii, Staphylococcus lentus, Staphylococcus lugdunensis, Staphylococcus muscae, Staphylococcus pasteuri, Staphylococcus saprophyticus, Staphylococcus warneri, and Staphylococcus xylosus. The antibacterial composition includes a first antibacterial protein consisting of the amino acid sequence as set forth in SEQ. ID. NO: 1 and/or a second antibacterial protein consisting of t e amino acid sequence as set forth in SEQ. ID. NO: 2. [0009] In an aspect, the antibacterial composition includes 15-35 mole % of t e first antibacterial protein and 55-85 mole % of the second antibacterial protein. [0010] In another aspect, the antibacterial composition includes 25 mole % of the first antibacterial protein and 75 mole % of the second antibacterial protein. [0011] In another aspect, the staphylococcal infections are skin infections, soft-tissue infections, toxic shock syndrome, purpura fulminans, endocarditis, osteomyelitis, pneumonia, infections related to prosthetic devices, or urinary tract infections. [0012] In another aspect, the skin infections are folliculitis, furuncles, impetigo, wound infections, or scalded skin syndrome. [0013] In another aspect, the soft-tissue infections are
Load more

Recommended publications
  • Intramammary Infections with Coagulase-Negative Staphylococcus Species
    Printing of this thesis was financially supported by Printed by University Press, Zelzate ISBN number: 9789058642738 INTRAMAMMARY INFECTIONS WITH COAGULASE-NEGATIVE STAPHYLOCOCCUS SPECIES IN BOVINES - MOLECULAR DIAGNOSTICS AND EPIDEMIOLOGY - KARLIEN SUPRÉ 2011 PROMOTORS/PROMOTOREN Prof. dr. Sarne De Vliegher Faculteit Diergeneeskunde, UGent Prof. dr. Ruth N. Zadoks Royal (Dick) School of Veterinary Studies, University of Edinburgh; Moredun Research Institute, Penicuik, Schotland Prof. dr. Freddy Haesebrouck Faculteit Diergeneeskunde, UGent MEMBERS OF THE EXAMINATION COMMITTEE/LEDEN VAN DE EXAMENCOMMISSIE Prof. dr. dr. h. c. Aart de Kruif Voorzitter van de examencommissie Prof. dr. Mario Vaneechoutte Faculteit Geneeskunde en Gezondheidswetenschappen, UGent Dr. Margo Baele Directie Onderzoeksaangelegenheden, UGent Dr. Lic. Luc De Meulemeester MCC-Vlaanderen, Lier Prof. dr. Geert Opsomer Faculteit Diergeneeskunde, UGent Prof. dr. Marc Heyndrickx Instituut voor Landbouw en Visserijonderzoek (ILVO), Melle Dr. Suvi Taponen University of Helsinki, Finland Prof. dr. Ynte H. Schukken Cornell University, Ithaca, USA INTRAMAMMARY INFECTIONS WITH COAGULASE-NEGATIVE STAPHYLOCOCCUS SPECIES IN BOVINES - MOLECULAR DIAGNOSTICS AND EPIDEMIOLOGY - KARLIEN SUPRÉ Department of Reproduction, Obstetrics, and Herd Health Faculty of Veterinary Medicine, Ghent University Dissertation submitted in the fulfillment of the requirements for the degree of Doctor in Veterinary Sciences, Faculty of Veterinary Medicine, Ghent University INTRAMAMMAIRE INFECTIES MET COAGULASE-NEGATIEVE
    [Show full text]
  • A Novel Approach to Eliminate Detection of Contaminating Staphylococcal Species Introduced During Clinical Testing
    RESEARCH ARTICLE A novel approach to eliminate detection of contaminating Staphylococcal species introduced during clinical testing Wanyuan Ao, Adrianne Clifford, Maylene Corpuz, Robert Jenison* Great Basin Corporation, Salt Lake City, Utah, United States of America * [email protected] a1111111111 a1111111111 Abstract a1111111111 a1111111111 We describe here a strategy that can distinguish between Staphylococcus species truly a1111111111 present in a clinical sample from contaminating Staphylococcus species introduced during the testing process. Contaminating Staphylococcus species are present at low levels in PCR reagents and colonize lab personnel. To eliminate detection of contaminants, we describe an approach that utilizes addition of sufficient quantities of either non-target Staph- OPEN ACCESS ylococcal cells (Staphylococcus succinus or Staphylococcus muscae) or synthetic oligonu- Citation: Ao W, Clifford A, Corpuz M, Jenison R cleotide templates to helicase dependent isothermal amplification reactions to consume (2017) A novel approach to eliminate detection of Staphylococcus-specific tuf and mecA gene primers such that contaminating Staphylococ- contaminating Staphylococcal species introduced cus amplification is suppressed to below assay limits of detection. The suppressor template during clinical testing. PLoS ONE 12(2): e0171915. DNA is designed with perfect homology to the primers used in the assay but an internal doi:10.1371/journal.pone.0171915 sequence that is unrelated to the Staphylococcal species targeted for detection. Input Editor: Baochuan Lin, Defense Threat Reduction amount of the suppressor is determined by a mathematical model described herein and is Agency, UNITED STATES demonstrated to completely suppress contaminating levels of Staphylococcus while not Received: October 25, 2016 negatively impacting the appropriate clinical assay limit of detection.
    [Show full text]
  • Posted 01/14
    FINAL REPORT BioReD: Biomarkers and Tools for Reductive Dechlorination Site Assessment, Monitoring and Management SERDP Project ER-1586 November 2013 Frank Löffler Kirsti Ritalahti University of Tennessee Elizabeth Edwards University of Toronto Carmen Lebrón NAVFAC ESC Distribution Statement A This report was prepared under contract to the Department of Defense Strategic Environmental Research and Development Program (SERDP). The publication of this report does not indicate endorsement by the Department of Defense, nor should the contents be construed as reflecting the official policy or position of the Department of Defense. Reference herein to any specific commercial product, process, or service by trade name, trademark, manufacturer, or otherwise, does not necessarily constitute or imply its endorsement, recommendation, or favoring by the Department of Defense. Form Approved REPORT DOCUMENTATION PAGE OMB No. 0704-0188 Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing this collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to Department of Defense, Washington Headquarters Services, Directorate for Information Operations and Reports (0704-0188), 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202- 4302. Respondents should be aware that notwithstanding any other provision of law, no person shall be subject to any penalty for failing to comply with a collection of information if it does not display a currently valid OMB control number. PLEASE DO NOT RETURN YOUR FORM TO THE ABOVE ADDRESS.
    [Show full text]
  • The Genera Staphylococcus and Macrococcus
    Prokaryotes (2006) 4:5–75 DOI: 10.1007/0-387-30744-3_1 CHAPTER 1.2.1 ehT areneG succocolyhpatS dna succocorcMa The Genera Staphylococcus and Macrococcus FRIEDRICH GÖTZ, TAMMY BANNERMAN AND KARL-HEINZ SCHLEIFER Introduction zolidone (Baker, 1984). Comparative immu- nochemical studies of catalases (Schleifer, 1986), The name Staphylococcus (staphyle, bunch of DNA-DNA hybridization studies, DNA-rRNA grapes) was introduced by Ogston (1883) for the hybridization studies (Schleifer et al., 1979; Kilp- group micrococci causing inflammation and per et al., 1980), and comparative oligonucle- suppuration. He was the first to differentiate otide cataloguing of 16S rRNA (Ludwig et al., two kinds of pyogenic cocci: one arranged in 1981) clearly demonstrated the epigenetic and groups or masses was called “Staphylococcus” genetic difference of staphylococci and micro- and another arranged in chains was named cocci. Members of the genus Staphylococcus “Billroth’s Streptococcus.” A formal description form a coherent and well-defined group of of the genus Staphylococcus was provided by related species that is widely divergent from Rosenbach (1884). He divided the genus into the those of the genus Micrococcus. Until the early two species Staphylococcus aureus and S. albus. 1970s, the genus Staphylococcus consisted of Zopf (1885) placed the mass-forming staphylo- three species: the coagulase-positive species S. cocci and tetrad-forming micrococci in the genus aureus and the coagulase-negative species S. epi- Micrococcus. In 1886, the genus Staphylococcus dermidis and S. saprophyticus, but a deeper look was separated from Micrococcus by Flügge into the chemotaxonomic and genotypic proper- (1886). He differentiated the two genera mainly ties of staphylococci led to the description of on the basis of their action on gelatin and on many new staphylococcal species.
    [Show full text]
  • Two-Component Signal Transduction System Saers Positively Regulates Staphylococcus Epidermidis Glucose Metabolism
    Hindawi Publishing Corporation e Scientific World Journal Volume 2014, Article ID 908121, 12 pages http://dx.doi.org/10.1155/2014/908121 Research Article Two-Component Signal Transduction System SaeRS Positively Regulates Staphylococcus epidermidis Glucose Metabolism Qiang Lou,1 Yijun Qi,1 Yuanfang Ma,1 and Di Qu2 1 Laboratory of Cellular and Molecular Immunology, Henan University, Kaifeng 475004, China 2 Key laboratory of Medical Molecular Virology of Ministry of Education and Ministry of Public Health, Institute of Medical Microbiology and Institutes of Biomedical Sciences, Shanghai Medical College of Fudan University, 138 Yixueyuan Road, Shanghai, 200032, China Correspondence should be addressed to Yuanfang Ma; [email protected] and Di Qu; [email protected] Received 30 August 2013; Accepted 21 November 2013; Published 23 January 2014 Academic Editors: D. Maiorano, H. Okamura, and M. Shiraishi Copyright © 2014 Qiang Lou et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Staphylococcus epidermidis, which is a causative pathogen of nosocomial infection, expresses its virulent traits such as biofilm and autolysis regulated by two-component signal transduction system SaeRS. In this study, we performed a proteomic analysis of differences in expression between the S. epidermidis 1457 wild-type and saeRS mutant to identify candidates regulated by saeRS using two-dimensional gel electrophoresis (2-DE) combined with matrix-assisted laser desorption/lonization mass spectrometry (MALDI-TOF-MS). Of 55 identified proteins that significantly differed in expression between the two strains, 15 were upregulated and 40 were downregulated.
    [Show full text]
  • Staphylococcus Debuckii Sp. Nov., a Coagulase-Negative Species from Bovine Milk
    TAXONOMIC DESCRIPTION Naushad et al., Int J Syst Evol Microbiol DOI 10.1099/ijsem.0.003457 Staphylococcus debuckii sp. nov., a coagulase-negative species from bovine milk Sohail Naushad,1,2,* Uliana Kanevets,1 Diego Nobrega,1,2 Domonique Carson,1,2 Simon Dufour,2,3 Jean-Philippe Roy,2,4 P. Jeffrey Lewis2,5 and Herman W. Barkema1,2 Abstract A novel type strain, designated SDB 2975T (=CECT 9737T=DSM 105892T), of the novel species Staphylococcus debuckii sp. nov. isolated from bovine milk is described. The novel species belongs to the genus Staphylococcus and showed resistance to tetracycline and was oxidase- and coagulase-negative, catalase-positive, and Gram-stain-positive. Phylogenetic relationships of Staphylococcus debuckii SDB 2975T to other staphylococcal species were inferred from 16S rRNA gene and whole- genome-based phylogenetic reconstruction. The 16S rRNA gene comparisons showed that the strain is closely related to Staphylococcus condimenti (99.73 %), Staphylococcus piscifermentans (99.66 %), Staphylococcus carnosus (99.59 %) and Staphylococcus simulans (98.03 %). Average nucleotide identity (ANI) values between S.taphylococcus debuckii SDB 2975T and its closely related Staphylococcus species were 83.96, 94.5, 84.03 and 78.09 %, respectively, and digital DNA–DNA hybridization (dDDH) values were 27.70, 58.02, 27.70 and 22.00 %, respectively. The genome of Staphylococcus debuckii SDB 2975T was sequenced with PacBio and Illumina technologies and is 2 691 850 bp long, has a G+C content of 36.6 mol% and contains 2678 genes and 80 RNAs, including six copies of each5S rRNA, 16S rRNA and 23S rRNA genes. Biochemical profiling and a newly developed PCR assay enabled differentiation of Staphylococcus debuckii SDB 2975T and three other SDB strains from its closest staphylococcal species.
    [Show full text]
  • Laboratory Procedure
    LABORATORY PROCEDURE BD Phoenix™ PMIC/ID Panels BD Phoenix™ PMIC Panels BD Phoenix™ PID Panels INTENDED USE The BD Phoenix™ Automated Microbiology System is intended for the in vitro rapid identification (ID) of Gram Positive bacteria from pure culture belonging to the genera Staphylococcus, Enterococcus, and other Gram Positive cocci and Gram Positive bacilli. The BD Phoenix Automated Microbiology System is also intended for the quantitative determination of antimicrobial susceptibility by minimal inhibitory concentration (MIC) of most Gram Positive bacteria from pure culture belonging to the genera Staphylococcus and Enterococcus. SUMMARY AND EXPLANATION OF THE TEST Micromethods for the biochemical identification of microorganisms were reported as early as 19181. Several publications reported on the use of the reagent-impregnated paper discs and micro-tube methods for differentiating enteric bacteria1-9. The interest in miniaturized identification systems led to the introduction of several commercial systems in the late 1960s, and they provided advantages in requiring little storage space, extended shelf life, standardized quality control, and ease of use. Many of the tests used in the Phoenix ID panels are modifications of the classical methods. These include tests for fermentation, oxidation, degradation and hydrolysis of various substrates. In addition to these, the Phoenix system utilizes chromogenic and fluorogenic substrates as well as single carbon source substrates in the identification of organisms10,11. The modern broth microdilution test used today has origins in the tube dilution test used in 1942 by Rammelkamp and Maxon to determine in vitro antimicrobial susceptibility testing of bacterial isolates from clinical specimens12. The broth dilution technique involves exposing bacteria to decreasing concentrations of antimicrobial agents in liquid media by serial two-fold dilutions.
    [Show full text]
  • Mastitisli Sütlerden Izole Edilen Stafilokoklarin Biyofilm Üretme Yeteneğinin Fenotipik Ve Genotipik Yöntemlerle Araştirilmasi
    T.C. ADNAN MENDERES ÜNİVERSİTESİ SAĞLIK BİLİMLER ENSTİTÜSÜ MİKROBİYOLOJİ ANABİLİM DALI MİK–YL–2015–0009 MASTİTİSLİ SÜTLERDEN İZOLE EDİLEN STAFİLOKOKLARIN BİYOFİLM ÜRETME YETENEĞİNİN FENOTİPİK VE GENOTİPİK YÖNTEMLERLE ARAŞTIRILMASI Yüksek Lisans Tezi Bahar KOÇ BÜYÜKTARAKÇI DANIŞMAN Doç. Dr. Serap SAVAŞAN AYDIN-2015 T.C. ADNAN MENDERES ÜNİVERSİTESİ SAĞLIK BİLİMLER ENSTİTÜSÜ MİKROBİYOLOJİ ANABİLİM DALI MİK–YL–2015–0009 MASTİTİSLİ SÜTLERDEN İZOLE EDİLEN STAFİLOKOKLARIN BİYOFİLM ÜRETME YETENEĞİNİN FENOTİPİK VE GENOTİPİK YÖNTEMLERLE ARAŞTIRILMASI Yüksek Lisans Tezi Bahar KOÇ BÜYÜKTARAKÇI DANIŞMAN Doç. Dr. Serap SAVAŞAN AYDIN-2015 ÖNSÖZ İnsan sağlığı ve beslenmesinde büyük öneme sahip olan süt, meme dokusunda meydana gelen değişiklikler nedeni ile sağlıklı mastitisli süt haline gelir. Mastit sağmal hayvanlarda mikroorganizmalar tarafından oluşturulan, meme bezlerinde iltihaba neden olan, doku yangısı ile karekterize meme hastalığıdır. Gerek ülkemizde ve gerekse diğer ülkelerde süt sığırı yetiştiriciliğinde ekonomik kayıplara yol açtığı için önemli bir sorun oluşturmuştur. Türkiye'de yılda 11 milyon ton süt üretildiği, süt ineklerinin % 30'unun mastitisli olduğu, mastitis nedeniyle süt verimindeki azalmanın %10 olduğu belirtilmektedir. Mastitisler toplam sığır hastalıklarının % 26'sını oluşturmaktadırlar. Ülkemizde önceki yıllarda yapılan araştırmalarda birçok mastitis vakası tespit edilmiş, tespit edilen vakaların çoğunluğunun subklinik olarak seyrettiği görülmüştür. Ülkemizde mastitisten kaynaklanan ekonomik kaybın yılda yaklaşık 57,7 milyon
    [Show full text]
  • Phylogenetic Analyses of Staphylococcus Based on the 16S Rdna Sequence and Assignment of Clinical Isolates from Animals
    Phylogenetic Analyses of Staphylococcus Based on the 16S rDNA Sequence and Assignment of Clinical Isolates from Animals Tatsufumi TAKAHASHI, Masayoshi KANEKO, Yukari MORI, Masayoshi TSUJI1), Naoya KIKUCHI, and Takashi HIRAMUNE Departments of Epizootiology and 1)Experimental Animals, School of Veterinary Medicine, Rakuno Gakuen University, Ebetsu 069, Japan (Received 18 February 1997/Accepted 12 May 1997) ABSTRACT. The nucleotide sequences of the 16S rDNA in 17 strains of 16 taxa of the genus Staphylococcus were determined. The sequences were compared phylogenetically together with the gene sequences of 10 (including 7 other species) Staphylococcus species retrieved from the DNA Data Bank of Japan. Although the primary and secondary structures of most of Staphylococcus species were very similar (homology values 96.4% or more) except for S. caseolyticus MAFF 911387T (homology values 95.4% or less), the 23 staphylococcal species were divided into 10 groups based on similarity, evolutionary distance and phylogenetic tree analysis. Nucleotide stretches in several variable domains in the 16S rDNA sequence appeared to be specific for the bacterial groups or the species. By comparing such characteristics in the sequence and phylogenies of 5 staphylococcal clinical isolates from bovine mastitis, canine and feline pyoderma, and feline urogenital syndrome with the information obtained in this study, the species level of each organism was identified. — KEY WORDS: rDNA, 16S ribosomal RNA, Staphylococcus. J. Vet. Med. Sci. 59(9): 775–783, 1997 Thirty-six taxa (species and subspecies) of the genus have indicated the existence of species-specific nucleotide Staphylococcus are listed in the American Type Culture stretches within the gene [3, 28, 39], however, the number Collection (ATCC) catalogue, updated in June 1996.
    [Show full text]
  • Wo 2009/140215 A2
    (12) INTERNATIONALAPPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date 19 November 2009 (19.11.2009) WO 2009/140215 A2 (51) International Patent Classification: (74) Agents: BROWDY AND NEIMARK, P.L.L.C. et al; A61K 31/47 (2006.01) A61P 31/10 (2006.01) 624 Ninth Street N.W., Suite 300, Washington, DC A61P 31/04 (2006.01) A61K 31/435 (2006.01) 20001-5303 (US). (21) International Application Number: (81) Designated States (unless otherwise indicated, for every PCT/US2009/043505 kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, (22) International Filing Date: CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, 11 May 2009 ( 11.05.2009) EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, (25) Filing Languag* English HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, (26) Publication Language: English MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, (30) Priority Data: NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, 61/052,2 12 11 May 2008 ( 11.05.2008) US SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, 61/053,040 14 May 2008 (14.05.2008) US UG, US, UZ, VC, VN, ZA, ZM, ZW. 61/056,032 26 May 2008 (26.05.2008) us (84) Designated States (unless otherwise indicated, for every 61/056,077 27 May 2008 (27.05.2008) us kind of regional protection available): ARIPO (BW, GH, 61/057,1 17 29 May 2008 (29.05.2008)
    [Show full text]
  • Proteomic Characterization of Bacteriophage Peptides from the Mastitis Producer Staphylococcus Aureus by LC-ESI-MS/MS and the Bacteriophage Phylogenomic Analysis
    foods Article Proteomic Characterization of Bacteriophage Peptides from the Mastitis Producer Staphylococcus aureus by LC-ESI-MS/MS and the Bacteriophage Phylogenomic Analysis Ana G. Abril 1 ,Mónica Carrera 2,* , Karola Böhme 3, Jorge Barros-Velázquez 4 , Benito Cañas 5, José-Luis R. Rama 1, Tomás G. Villa 1 and Pilar Calo-Mata 4,* 1 Department of Microbiology and Parasitology, Faculty of Pharmacy, University of Santiago de Compostela, 15898 Santiago de Compostela, Spain; [email protected] (A.G.A.); [email protected] (J.-L.R.R.); [email protected] (T.G.V.) 2 Department of Food Technology, Spanish National Research Council, Marine Research Institute, 36208 Vigo, Spain 3 Agroalimentary Technological Center of Lugo, 27002 Lugo, Spain; [email protected] 4 Department of Analytical Chemistry, Nutrition and Food Science, School of Veterinary Sciences, University of Santiago de Compostela, 27002 Lugo, Spain; [email protected] 5 Department of Analytical Chemistry, Complutense University of Madrid, 28040 Madrid, Spain; [email protected] * Correspondence: [email protected] (M.C.); [email protected] (P.C.-M.) Abstract: The present work describes LC-ESI-MS/MS MS (liquid chromatography-electrospray ionization-tandem mass spectrometry) analyses of tryptic digestion peptides from phages that infect mastitis-causing Staphylococcus aureus isolated from dairy products. A total of 1933 nonredundant Citation: Abril, A.G.; Carrera, M.; peptides belonging to 1282 proteins were identified and analyzed. Among them, 79 staphylococcal Böhme, K.; Barros-Velázquez, J.; peptides from phages were confirmed. These peptides belong to proteins such as phage repressors, Cañas, B.; Rama, J.-L.R.; Villa, T.G.; structural phage proteins, uncharacterized phage proteins and complement inhibitors.
    [Show full text]
  • Microbiology
    MICROBIOLOGY Smart identification and antibiotic susceptibility determination system MIKROLATEST® MIC MIKROLATEST® BP MIKROLATEST® ID MIKROLA® MICROBIOLOGY Erba Lachema s. r. o., a traditional producer and supplier of diagnostic products for clinical laboratories, offers an advanced range of products for microbial identification and antibiotic susceptibility determination. Contents: MIKROLATEST® MIC 2 High quality system for antibiotic susceptibility testing based on minimal inhibitory concentration determination designed for visual or automated reading. MIKROLATEST® BP 6 Economical system for antibiotic susceptibility testing based on EUCAST breakpoint determination designed for visual or automated reading. MIKROLATEST® ID 9 User-friendly kits for microbial identification using traditional biochemical tests designed for visual or automated reading. MIKROLA® Softwares 34 Smart microbiological system for computer aided evaluation of MIKROLATEST ID, MIKROLATEST BP and MIKROLATEST MIC tests and data management. System for susceptibility interpretation according to EUCAST and CLSI guidelines. MIKROLA® Readers 35 Handy photometers for automated reading and evaluation of MIKROLATEST MIC, MIKROLATEST BP and MIKROLATEST MIC. Applicable for immunology as well. MIKROLA® Accessories 36 Additional tools intended to ease the use of MIKROLATEST® products. MIKROLATEST® MIC Minimum inhibitory concentration AST kits Principle of the method: This method allows quantitative determination of minimum inhibitory concentration of antibiotics in preselected panels.
    [Show full text]